SARS-CoV-2 Nanobody Library Screening for Variant Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing therapeutic interventions against COVID-19, such as high titer convalescent plasma and monoclonal antibody therapies, face challenges like batch-to-batch variability and limited adaptability to emerging virus variants, necessitating the need for rapid and effective neutralizing antibodies that can target multiple variants of SARS-CoV-2.
Innovation Solution
The development of isolated or purified nanobodies that bind to SARS-CoV-2 variants, specifically the spike protein or receptor-binding domain, identified through a rapid library screening process, which can be engineered to bind to multiple sites on the virus, enhancing immune response and adaptability to various variants, and can be administered via aerosol or injection, offering improved manufacturability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibody therapies are used, then neutralizing activity against SARS-CoV-2 is achieved, but batch-to-batch variability and limited adaptability to emerging variants occur
Solution Approach 1:
The patent develops nanobody cocktails that can simultaneously target multiple SARS-CoV-2 variants and different viral proteins (spike, nucleocapsid, membrane). The nanobodies are designed with broad-spectrum neutralizing activity against multiple variants including Alpha, Beta, Gamma, Delta, and Omicron, making a single therapeutic formulation universally effective across evolving viral strains without requiring batch-specific customization
2Loss of time
If rapid response to emerging variants is needed, then development time must be reduced, but traditional antibody development methods are time-consuming
Solution Approach 1:
The patent employs pre-selected nanobody candidates with known broad-spectrum neutralizing properties that can be rapidly deployed when new variants emerge. The nanobody library and selection platform are established in advance, allowing immediate screening and formulation of variant-specific or pan-variant cocktails without needing to start antibody development from scratch when outbreaks occur
Solution Approach 2:
The patent utilizes phage display technology and in vitro selection methods that dramatically accelerate antibody development compared to traditional in vivo immunization approaches. By using synthetic nanobody libraries and high-throughput screening platforms, the development timeline is compressed from years to months or weeks, enabling rapid response to emerging variants while maintaining high affinity and specificity
3Quantity of substance
If high titer convalescent plasma is used for treatment, then neutralizing antibodies are provided, but batch-to-batch variability limits reliability
Solution Approach 1:
The patent uses recombinant nanobody technologies to create precise copies of neutralizing antibody sequences identified from convalescent plasma or engineered de novo. These synthetic nanobodies are produced through recombinant expression systems, eliminating the batch-to-batch variability inherent in plasma-derived products while preserving the neutralizing activity. Each nanobody batch is genetically identical and can be manufactured with consistent quality attributes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These nanobodies demonstrate significant affinity and neutralization capabilities against multiple SARS-CoV-2 variants, including Delta and Omicron, providing a rapid and adaptable therapeutic solution with enhanced binding properties and easier manufacturing compared to conventional antibodies.
Implementation Method 1
an isolated or purified nanobody, or a construct comprising such nanobody, that binds to a SARS-COV-2 variant or a portion thereof (e.g., the spike protein or receptor-binding domain (RBD) of the spike protein)
Data Source
AI summary
A large and highly diverse nanobody library was constructed and screened against multiple variants of SARS-COV-2 to find nanobodies with high sensitivity and specificity for the variants. Four rounds of positive selection against a panel of six diverse SARS-COV-2 variant RBDs was performed with our high-diversity. At least 59 of these nanobodies were found to work well against Alpha, Beta, Gamma, Delta, Kappa, Lambda and Mu with some overlap efficacy against other variants. These nanobodies have efficacy as stand-alone nanobodies and as a construct comprising nanobodies linked to the human IgG1 constant fragment (Fc) (nanobody-hFc constructions or nb-hFcs) to make enhanced humanized sdAbs with all the attributes of nanobodies with improved half-life and optimized effector functions. Several promising nanobodies that neutralize the original SARS-COV-2 and several of its variants have been identified, including Delta, with high efficacy. In particular, a subset of these nanobodies bind to the Omicron RBD.